-+ 0.00%
-+ 0.00%
-+ 0.00%

Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD

PUBT·06/22/2026 20:31:12
Listen to the news
Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD
  • Definium highlighted DT120 ODT, a single-dose lysergide therapy, as its lead late-stage program in five Phase 3 studies for GAD, MDD.
  • Emerge Phase 3 topline data in MDD met the primary endpoint; 8.1-point MADRS improvement over placebo at week 6 (p<0.0001).
  • Durability signal extended to week 12; 7.3-point MADRS improvement over placebo (p<0.0001); CGI-S improved by 0.9 at day 2 (p<0.0001).
  • Safety update showed no serious adverse events in Emerge through week 12; 99% of AEs were mild-to-moderate; no suicidality signal.
  • Balance sheet showed cash, cash equivalents, investments of USD 373.4 million as of March 31, 2026; runway expected into 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.